Cha Albert

CIK 00013979069 companiesHELLERUP

SEC Profile

Transactions

Companies

Filings

CIK

0001397906

Recent Transactions

50 trades

Award
KalVista Pharmaceuticals, Inc.$KALV
Stock Option (right to buy)
2023-09-26+10,000→ 10,000 total
Exercise/Conversion
KalVista Pharmaceuticals, Inc.$KALV
Employee Stock Option (right to buy)
2023-09-11−6,000→ 0 total
Exercise/Conversion
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2023-09-11$7.88/sh+12,000→ 18,000 total
Exercise/Conversion
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2023-09-11$6.71/sh+6,000→ 6,000 total
Sale
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2023-09-11$10.50/sh−18,000→ 0 total
Exercise/Conversion
KalVista Pharmaceuticals, Inc.$KALV
Employee Stock Option (right to buy)
2023-09-11−12,000→ 0 total
Award
KalVista Pharmaceuticals, Inc.$KALV
Employee Stock Option (right to buy)
2022-10-13+10,000→ 10,000 total
Award
KalVista Pharmaceuticals, Inc.$KALV
Director Stock Option (Right to Buy)
2021-09-30+10,000→ 10,000 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2020-10-30$17.17/sh+68,255→ 1,090,748 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2020-10-30$17.34/sh+47,431→ 1,138,179 total
Award
KalVista Pharmaceuticals, Inc.$KALV
Director Stock Option (right to buy)
2020-10-01+7,000→ 7,000 total
Award
KalVista Pharmaceuticals, Inc.$KALV
Director Stock Option (Right to Buy)
2019-10-02+7,000→ 7,000 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2019-07-29$17.13/sh+5,137→ 124,566 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2019-07-29$17.13/sh+24,730→ 1,022,493 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2019-07-26$16.83/sh+4,558→ 119,429 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2019-07-26$16.83/sh+21,942→ 997,763 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2019-07-19$17.84/sh+49,680→ 975,821 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2019-07-19$17.68/sh+10,320→ 114,871 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2019-07-17$16.97/sh+1,060→ 926,141 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2019-07-17$16.93/sh+220→ 104,551 total
Award
KalVista Pharmaceuticals, Inc.$KALV
Director Stock Option (Right to Buy)
2018-10-03+7,000→ 7,000 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2018-09-10$17.00/sh+1,058,824→ 1,359,149 total
Award
Biohaven Pharmaceutical Holding Co Ltd.
Stock Option (Right to Buy)
2018-05-01+18,000→ 18,000 total
Award
Biohaven Pharmaceutical Holding Co Ltd.
Common Shares
2018-03-14$27.50/sh+72,727→ 2,049,545 total
Conversion
VYNE Therapeutics Inc.$VYNE
Series C Preferred Stock
2018-01-29−2,475,118→ 0 total
Conversion
VYNE Therapeutics Inc.$VYNE
Common Stock
2018-01-29+126,703→ 486,695 total
Conversion
VYNE Therapeutics Inc.$VYNE
Common Stock
2018-01-29+324,306→ 359,992 total
Conversion
VYNE Therapeutics Inc.$VYNE
Common Stock
2018-01-29+917,559→ 3,524,541 total
Conversion
VYNE Therapeutics Inc.$VYNE
Series B Preferred Stock
2018-01-29−874,817→ 0 total
Conversion
VYNE Therapeutics Inc.$VYNE
Series C Preferred Stock
2018-01-29−341,784→ 0 total
Conversion
VYNE Therapeutics Inc.$VYNE
Common Stock
2018-01-29+2,348,550→ 2,606,982 total
Conversion
VYNE Therapeutics Inc.$VYNE
Series B Preferred Stock
2018-01-29−6,335,215→ 0 total
Purchase
VYNE Therapeutics Inc.$VYNE
Common Stock
2018-01-25$17.00/sh+258,432→ 258,432 total
Purchase
VYNE Therapeutics Inc.$VYNE
Common Stock
2018-01-25$17.00/sh+35,686→ 35,686 total
Award
KalVista Pharmaceuticals, Inc.$KALV
Director Stock Option (Right to Buy)
2017-09-27+6,000→ 6,000 total
Purchase
Biohaven Pharmaceutical Holding Co Ltd.
Common Shares
2017-05-09$17.00/sh+470,000→ 1,976,818 total
Conversion
Biohaven Pharmaceutical Holding Co Ltd.
Series A Preferred Shares
2017-05-09−1,506,818→ 0 total
Conversion
Biohaven Pharmaceutical Holding Co Ltd.
Common Shares
2017-05-09+1,506,818→ 1,506,818 total
Award
KalVista Pharmaceuticals, Inc.$KALV
Director Stock Option (Right to Buy)
2017-03-23+12,000→ 12,000 total
Award
Aclaris Therapeutics, Inc.$ACRS
Stock Option (right to buy)
2016-06-29+6,632→ 6,632 total
Conversion
Aclaris Therapeutics, Inc.$ACRS
Series C Preferred Stock
2015-10-13−1,375,405→ 0 total
Conversion
Aclaris Therapeutics, Inc.$ACRS
Common Stock
2015-10-13+3,433,646→ 3,736,852 total
Conversion
Aclaris Therapeutics, Inc.$ACRS
Series A Preferred Stock
2015-10-13−8,652,500→ 0 total
Purchase
Aclaris Therapeutics, Inc.$ACRS
Common Stock
2015-10-13$11.00/sh+454,545→ 4,191,397 total
Conversion
Aclaris Therapeutics, Inc.$ACRS
Series B Preferred Stock
2015-10-13−1,818,182→ 0 total
Purchase
Aclaris Therapeutics, Inc.$ACRS
Common Stock
2015-10-07$11.00/sh+13,352→ 303,206 total
Conversion
Sierra Oncology, Inc.
Common Stock
2015-07-21+44,991→ 2,109,299 total
Other
Sierra Oncology, Inc.
Common Stock
2015-07-21$5.21/sh+106,647→ 2,215,946 total
Other
Sierra Oncology, Inc.
Common Stock
2015-07-21$5.21/sh+2,324→ 2,218,270 total
Conversion
Sierra Oncology, Inc.
Common Stock
2015-07-21+2,064,308→ 2,064,308 total

Companies

Recent Filings

Address

C/O ASCENDIS PHARMA A/S TUBORG BOULEVARD 12

HELLERUP, DK-2900

View on SEC.gov